Global and China trends and forecasts of disease burden for female lung Cancer from 1990 to 2021: a study based on the global burden of disease 2021 database by Bilu Li, Yuyan Wu, Yanhong Zhang, Chengyun Hu, Xue Li, Shanshan Luo, Chenyu Sun, Iyad Yousef, Yefei Wang, Chaoliang Tang

Subjects: Get full text

PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials by Samuel Pratama, Lowilius Wiyono, Martien Silviandy Setiawan, Brigitta Cindy Lauren

Subjects: Get full text

Influence of symptom burden on social alienation in lung cancer patients receiving chemotherapy: the chain mediating effect of perceived social support and positive psychological capital by Jiahao Wei, Ziye Bai, Mengru Bu, Guining Dang, Xiumei Wu, Jin Zhou

Subjects: “…Lung cancer chemotherapy…”
Get full text

Non-cancerous CT findings as predictors of survival outcome in advanced non-small cell lung cancer patients treated with first-generation EGFR-TKIs. by Pakorn Prakaikietikul, Pattraporn Tajarenmuang, Phumiphat Losuriya, Natee Ina, Thanika Ketpueak, Thanat Kanthawang

“…<h4>Purpose</h4>To identify non-cancerous factors from baseline CT chest affecting survival in advanced non-small cell lung cancer (NSCLC) treated with first-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs).…”
Get full text

CTSG is a prognostic marker involved in immune infiltration and inhibits tumor progression though the MAPK signaling pathway in non-small cell lung cancer by Qian Dai, Xufeng Yao, Yanke Zhang, Qian Chai, Xueyi Feng, Hongbin Zhu, Lei Zhao

“…Abstract Purpose This study aims to investigate the biological roles and molecular mechanisms of Cathepsin G (CTSG) in the progression of non-small cell lung cancer (NSCLC). Methods Western blotting and immunohistochemistry analyses of clinical samples were performed to determine the expression levels of CTSG in patients with NSCLC. …”
Get full text

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report by Oliver Illini, Anna Sophie Lang-Stöberl, Hannah Fabikan, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair

Subjects: Get full text

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer by Jing Zhang, Wenjie Li

“…Abstract Background While clinical trials have demonstrated enduring responses to amivantamab among advanced non-small cell lung cancer (NSCLC) patients bearing EGFR exon 20 insertion mutations, the associated toxicity profile in real-world scenarios remains elusive. …”
Get full text

Analysis of tumor-infiltrating exhausted T cells highlights IL-6 and PD1 blockade as a combined immunotherapy strategy for non-small cell lung cancer by Lulu Zhang, Lulu Zhang, Xiyuan Guo, Xiyuan Guo, Xiaoke Sun, Jue Liao, Qin Liu, Yingchun Ye, Zhihui Yang, Ratchada Cressey, Qing He, Qing Yuan, Qing Yuan

Subjects: Get full text

Design of a Medium Scale Ambient PM2.5 Cleaning System by Sheng-Chieh Chen, Qingfeng Cao, Thomas H. Kuehn, Charles Lo, Manoranjan Sahu, Yelia S. Mayya, David Y. H. Pui

Subjects: Get full text

Comparing survival outcomes of localized tumor destruction, sublobar resection, and pulmonary lobectomy in stage IA non-small cell lung cancer: a study from the SEER database by Lin Cheng, Sheng-Wei Li, Xiao-Guang Li

Subjects: Get full text

Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis by Mariana M. Sebastião, Rodrigo S. Ho, João Paulo V. de Carvalho, Micha Nussbaum

“…**Background/Objectives:** Until now, no meta-analysis has been published to evaluate the diagnostic performance of next-generation sequencing (NGS) panel using circulating tumor (ctDNA) in patients with advanced non-small cell lung cancer (aNSCLC). The aim of the study was to carry out a systematic review and a meta-analysis in order to determine the accuracy of NGS of ctDNA to detect six oncogenic driver alterations: epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK); ROS proto-oncogene 1, receptor tyrosine kinase (ROS-1); serine/threonine-protein kinase B-RAF (BRAF); RET proto-oncogene (RET); and MET proto-oncogene, receptor tyrosine kinase (MET) exon 14 in patients with aNSCLC. …”
Get full text

Identification of prognostic biomarker of non-small cell lung cancer based on mitochondrial permeability transition-driven necrosis-related genes and determination of anti-tumor effect of ARL14 by Zhifei Ma, Wen Chen, Aiping Zhang, Xiaokang Shen, Lin Zheng

Subjects: “…Non-small cell lung cancer…”
Get full text

Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy by Meifeng Luo, Huiting Wei, Moqin Qiu, Cuiyun Su, Ruiling Ning, Shaozhang Zhou

Subjects: Get full text

Functional status, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio as prognostic factors of one-year survival rate in elderly patients with advanced-stage non-small cell lung cancer by Ratna Nurhayati, Aulia Rizka, Cleopas Martin Rumende, Noorwati Sutandyo, Arif Hanafi, Edy Rizal Wahyudi, Hamzah Shatri, Anna Mira Lubis, Em Yunir, Muhammad Firdaus, Yuniar Harris Prayitno, Nadira Nibras Taqiyya

“…Background and aim: Non-small cell lung cancer (NSCLC) is the most common lung cancer found in elderly patients. …”
Get full text

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system by Ruichen Gao, Wenjun Liang, Jintao Chen, Mingxia Yang, Xiaowei Yu, Xiaohua Wang

Subjects: Get full text

Klinefelter syndrome diagnosed at autopsy and small-cell lung carcinoma by Haruyasu Sakuranaka, Ryoma Tanaka, Yuji Yamakawa, Shiho Yamada, Komei Igei, Yasuo Asai

Subjects: Get full text

NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model by Ismail M Meraz, Mourad Majidi, Renduo Song, Feng Meng, Lihui Gao, Qi Wang, Jing Wang, Elizabeth J Shpall, Jack A Roth

Get full text

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

Subjects: “…Nonsquamous non-small cell lung cancer…”
Get full text

MAEMC-NET: a hybrid self-supervised learning method for predicting the malignancy of solitary pulmonary nodules from CT images by Tianhu Zhao, Tianhu Zhao, Yong Yue, Hang Sun, Jingxu Li, Yanhua Wen, Yudong Yao, Wei Qian, Yubao Guan, Shouliang Qi, Shouliang Qi

Subjects: “…lung cancer…”
Get full text

Author Correction: Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells by Marta Buzzetti, Sonia Morlando, Dimitrios Solomos, Ammara Mehmood, Alexander W. I. Cox, Mattia Chiesa, Yuri D’Alessandra, Michela Garofalo, Caroline H. Topham, Gianpiero Di Leva

Get full text